Melanoma Clinical Trials in North Carolina

Showing 21-40 of 146 trials

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

NCT03454035

This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4/6 inhibitor palbociclib.

Tumor, SolidPancreatic CancerMelanoma

UNC Lineberger Comprehensive Cancer Center45 participantsStarted Jan 2018

Chapel Hill, North Carolina, United States

RECRUITING46 miles

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

Bladder CarcinomaUreter CarcinomaRenal Pelvis Carcinoma+13 more

Guardant Health, Inc.2,020 participantsStarted Sep 2021

Birmingham, Alabama, United States • Chandler, Arizona, United States • Hot Springs, Arkansas, United States +54 more locations

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Melanoma Trials in Other Cities

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Patient Satisfaction With Appearance, Scar Outcome and Quality of Life After Skin Cancer Surgery

Other Conditions in North Carolina